Quantitative structure–pharmacokinetic relationships

Importance of the field: Quantitative structure–pharmacokinetic relationships (QSPKR) modeling is a valuable tool in drug discovery and development. It can provide insights into the molecular determinants of processes governing the time course of drug exposure and response. Areas covered in this review: Empirical and mechanism-based QSPKR models are discussed, including specific examples for oral absorption, nonspecific protein binding, volume of distribution, total metabolic stability and specific interactions with drug metabolizing enzymes. Emphasis is placed on state-of-the-art techniques, including new approaches for the direct simulation of concentration–time profiles from molecular descriptors (temporal QSPKR). What the reader will gain: Reviewing the application of current QSPKR modeling techniques will place these methods in context and highlight their respective advantages and limitations, as well as opportunities for further refinement. Take home message: The expansion of readily available molecular descriptors and advanced algorithms has improved empirical models and enabled the development of robust models for non-congeneric series. Empirical models focus on point estimates of global PK processes and physiologically-based models may be more desirable than data-driven methods. Further integration of relevant biological and pharmacological mechanisms will improve the ability to predict the full time course of drug concentration and effect profiles for diverse compounds and experimental conditions.

[1]  Kairui Feng,et al.  The Simcyp® Population-based ADME Simulator , 2009 .

[2]  Jin Sun,et al.  Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. , 2009, European journal of medicinal chemistry.

[3]  Leo Breiman,et al.  Bagging Predictors , 1996, Machine Learning.

[4]  Kairui Feng,et al.  The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.

[5]  Fahima Nekka,et al.  Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. , 2010, Journal of pharmaceutical sciences.

[6]  Yoshitaka Yano,et al.  Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. , 2004, Journal of pharmaceutical sciences.

[7]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[8]  Kazuya Maeda,et al.  Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.

[9]  M. Thomson,et al.  Intestinal Metabolism and Transport of Drugs in Children: The Effects of Age and Disease , 2008, Journal of pediatric gastroenterology and nutrition.

[10]  Joseph V. Turner,et al.  Bioavailability Prediction Based on Molecular Structure for a Diverse Series of Drugs , 2004, Pharmaceutical Research.

[11]  S. Ekins,et al.  Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. , 1999, The Journal of pharmacology and experimental therapeutics.

[12]  Berith F. Jensen,et al.  In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. , 2007, Journal of medicinal chemistry.

[13]  A. Tropsha,et al.  Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. , 2003, Journal of medicinal chemistry.

[14]  Peter E. Hart,et al.  Nearest neighbor pattern classification , 1967, IEEE Trans. Inf. Theory.

[15]  Gisbert Schneider,et al.  Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.

[16]  R. Bursi,et al.  (Q) SAR study on the metabolic stability of steroidal androgens. , 2001, Journal of molecular graphics & modelling.

[17]  Hannah M Jones,et al.  SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS , 2004, Drug Metabolism and Disposition.

[18]  Nikhil S. Ketkar,et al.  High confidence predictions of drug-drug interactions: predicting affinities for cytochrome P450 2C9 with multiple computational methods. , 2008, Journal of medicinal chemistry.

[19]  J V Gobburu,et al.  Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis. , 1996, Journal of pharmaceutical sciences.

[20]  M. Rowland,et al.  Relationship between lipophilicity and tubular reabsorption for a series of 5-alkyl-5-ethylbarbituric acids in the isolated perfused rat kidney preparation. , 1988, Journal of pharmaceutical sciences.

[21]  M. Karelson Molecular descriptors in QSAR/QSPR , 2000 .

[22]  B. Kowalski,et al.  Partial least-squares regression: a tutorial , 1986 .

[23]  David A Winkler,et al.  Neural networks as robust tools in drug lead discovery and development , 2004, Molecular biotechnology.

[24]  F. Theil,et al.  Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. , 2001, Journal of pharmaceutical sciences.

[25]  Y. Sugiyama,et al.  Prediction of hepatic first-pass metabolism and plasma levels following intravenous and oral administration of barbiturates in the rabbit based on quantitative structure—Pharmacokinetic relationships , 1988, Journal of Pharmacokinetics and Biopharmaceutics.

[26]  Anders Karlén,et al.  Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[27]  Yojiro Sakiyama,et al.  Predicting human liver microsomal stability with machine learning techniques. , 2008, Journal of molecular graphics & modelling.

[28]  L. Aarons,et al.  Quantitative Structure-Pharmacokinetics Relationships: I. Development of a Whole-Body Physiologically Based Model to Characterize Changes in Pharmacokinetics Across a Homologous Series of Barbiturates in the Rat , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[29]  Tingjun Hou,et al.  ADME evaluation in drug discovery , 2002, Journal of molecular modeling.

[30]  Hao Sun,et al.  Structure‐based Drug Metabolism Predictions for Drug Design , 2010, Chemical biology & drug design.

[31]  Ravi Iyengar,et al.  Network analyses in systems pharmacology , 2009, Bioinform..

[32]  Johannes Grotendorst,et al.  Classification of Highly Unbalanced CYP450 Data of Drugs Using Cost Sensitive Machine Learning Techniques , 2007, J. Chem. Inf. Model..

[33]  Seung-Hoon Choi,et al.  Artificial neural network models for prediction of intestinal permeability of oligopeptides , 2007, BMC Bioinformatics.

[34]  M Jamei,et al.  Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. , 2009, Current drug metabolism.

[35]  Chris de Graaf,et al.  Cytochrome p450 in silico: an integrative modeling approach. , 2005, Journal of medicinal chemistry.

[36]  B. Hill,et al.  Predicting human drug pharmacokinetics from in vitro permeability using an absorption-disposition model. , 2007, Journal of pharmaceutical sciences.

[37]  Franco Lombardo,et al.  Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. , 2004, Journal of medicinal chemistry.

[38]  S Oie,et al.  Effect of altered plasma protein binding on apparent volume of distribution. , 1979, Journal of pharmaceutical sciences.

[39]  M Paul Gleeson,et al.  In silico human and rat Vss quantitative structure-activity relationship models. , 2006, Journal of medicinal chemistry.

[40]  Jing Lu,et al.  Development of in silico models for human liver microsomal stability , 2007, J. Comput. Aided Mol. Des..

[41]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 8. The Prediction of Human Intestinal Absorption by a Support Vector Machine , 2007, J. Chem. Inf. Model..

[42]  P. Hinderling,et al.  Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man , 1984, Journal of Pharmacokinetics and Biopharmaceutics.

[43]  Yan Li,et al.  Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism. , 2005, Bioorganic & medicinal chemistry letters.

[44]  Yoshua Bengio,et al.  Pattern Recognition and Neural Networks , 1995 .

[45]  G L Amidon,et al.  A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.

[46]  S. Ekins,et al.  Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.

[47]  N. Pyszczynski,et al.  Integrated QSPR--pharmacodynamic model of genomic effects of several corticosteroids. , 2003, Journal of pharmaceutical sciences.

[48]  Han van de Waterbeemd,et al.  Lipophilicity in PK design: methyl, ethyl, futile , 2001, J. Comput. Aided Mol. Des..

[49]  Ying Zhang,et al.  In Silico Modeling of Nonspecific Binding to Human Liver Microsomes , 2008, Drug Metabolism and Disposition.

[50]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. , 2002, Journal of pharmaceutical sciences.

[51]  W Wang,et al.  Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.

[52]  L. Berezhkovskiy,et al.  Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. , 2004, Journal of pharmaceutical sciences.

[53]  Joseph P Balthasar,et al.  Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. , 2010, Journal of pharmaceutical sciences.

[54]  S. O'Brien,et al.  Greater than the sum of its parts: combining models for useful ADMET prediction. , 2005, Journal of medicinal chemistry.

[55]  Yojiro Sakiyama The use of machine learning and nonlinear statistical tools for ADME prediction. , 2009, Expert opinion on drug metabolism & toxicology.

[56]  Chunxin Zhang,et al.  Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. , 2007, Nanomedicine : nanotechnology, biology, and medicine.

[57]  Junmei Wang,et al.  Genetic Algorithm-Optimized QSPR Models for Bioavailability, Protein Binding, and Urinary Excretion , 2006, J. Chem. Inf. Model..

[58]  K Krishnan,et al.  An integrated QSPR–PBPK modelling approach for in vitro–in vivo extrapolation of pharmacokinetics in rats , 2008, SAR and QSAR in environmental research.

[59]  Sunwoo Park,et al.  Predictions of Hepatic Disposition Properties Using a Mechanistically Realistic, Physiologically Based Model , 2008, Drug Metabolism and Disposition.

[60]  Michael Gertz,et al.  Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data , 2008, Drug Metabolism and Disposition.

[61]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[62]  Donald E. Mager,et al.  General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[63]  Kristina Luthman,et al.  Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans , 1997, Pharmaceutical Research.

[64]  Gilles Klopman,et al.  ADME evaluation. 2. A computer model for the prediction of intestinal absorption in humans. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[65]  Scott Boyer,et al.  Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models , 2007, J. Comput. Aided Mol. Des..

[66]  Gordon L Amidon,et al.  A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.

[67]  L. Aarons,et al.  Quantitative Structure–Pharmacokinetics Relationships: II. A Mechanistically Based Model to Evaluate the Relationship Between Tissue Distribution Parameters and Compound Lipophilicity , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[68]  Søren Balling Engelsen,et al.  Prediction of in vitro metabolic stability of calcitriol analogs by QSAR , 2003, J. Comput. Aided Mol. Des..

[69]  E. Gifford,et al.  The development and validation of a computational model to predict rat liver microsomal clearance. , 2009, Journal of pharmaceutical sciences.

[70]  Shraddha S. Nigavekar,et al.  3H Dendrimer Nanoparticle Organ/Tumor Distribution , 2004, Pharmaceutical Research.

[71]  Alexander Tropsha,et al.  QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation. , 2006, Journal of medicinal chemistry.

[72]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[73]  W. Jusko,et al.  Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. , 2002, Journal of pharmaceutical sciences.

[74]  Franco Lombardo,et al.  Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds , 2008, Drug Metabolism and Disposition.

[75]  S. Ekins,et al.  Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[76]  Jaina Mistry,et al.  A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries. , 2005, Journal of medicinal chemistry.

[77]  Junmei Wang,et al.  Structure – ADME relationship : still a long way to go ? , 2008 .

[78]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[79]  Richard J. Povinelli,et al.  Synergistic Use of Compound Properties and Docking Scores in Neural Network Modeling of CYP2D6 Binding: Predicting Affinity and Conformational Sampling , 2006, J. Chem. Inf. Model..

[80]  K. Bischoff,et al.  Interspecies correlation of plasma concentration history of methotrexate (NSC-740). , 1970, Cancer chemotherapy reports.

[81]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 7. Prediction of Oral Absorption by Correlation and Classification , 2007, J. Chem. Inf. Model..

[82]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[83]  Scott L Cockroft,et al.  The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[84]  Tudor I. Oprea,et al.  Integrating virtual screening in lead discovery. , 2004, Current opinion in chemical biology.

[85]  Jan M. Kriegl,et al.  Computational approaches to predict drug metabolism. , 2009, Expert opinion on drug metabolism & toxicology.

[86]  D. K. Arrell,et al.  Network Systems Biology for Drug Discovery , 2010, Clinical pharmacology and therapeutics.

[87]  S. Ekins,et al.  Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. , 1999, Pharmacogenetics.

[88]  G. Schneider,et al.  A Virtual Screening Filter for Identification of Cytochrome P450 2C9 (CYP2C9) Inhibitors , 2007 .

[89]  D L Massart,et al.  Classification of drugs in absorption classes using the classification and regression trees (CART) methodology. , 2005, Journal of pharmaceutical and biomedical analysis.

[90]  Klaus-Robert Müller,et al.  A Probabilistic Approach to Classifying Metabolic Stability , 2008, J. Chem. Inf. Model..

[91]  Marjo Yliperttula,et al.  Computational prediction of oral drug absorption based on absorption rate constants in humans. , 2006, Journal of medicinal chemistry.

[92]  A. Galetin,et al.  Drug Lipophilicity and Microsomal Protein Concentration as Determinants in the Prediction of the Fraction Unbound in Microsomal Incubations , 2008, Drug Metabolism and Disposition.

[93]  Bernd Beck,et al.  A support vector machine approach to classify human cytochrome P450 3A4 inhibitors , 2005, J. Comput. Aided Mol. Des..

[94]  Y. Z. Chen,et al.  Quantitative Structure-Pharmacokinetic Relationships for drug distribution properties by using general regression neural network. , 2005, Journal of pharmaceutical sciences.

[95]  Patrick Poulin,et al.  Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. , 2009, Journal of pharmaceutical sciences.

[96]  Vladimir N. Vapnik,et al.  The Nature of Statistical Learning Theory , 2000, Statistics for Engineering and Information Science.

[97]  Glen E. P. Ropella,et al.  Tracing Multiscale Mechanisms of Drug Disposition in Normal and Diseased Livers , 2010, Journal of Pharmacology and Experimental Therapeutics.

[98]  Franco Lombardo,et al.  Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. , 2002, Journal of medicinal chemistry.

[99]  Gábor Csányi,et al.  Gaussian Processes: A Method for Automatic QSAR Modeling of ADME Properties , 2007, J. Chem. Inf. Model..

[100]  G. Amidon,et al.  Absorption potential: estimating the fraction absorbed for orally administered compounds. , 1985, Journal of pharmaceutical sciences.

[101]  Z R Li,et al.  Quantitative structure-pharmacokinetic relationships for drug clearance by using statistical learning methods. , 2006, Journal of molecular graphics & modelling.

[102]  Quantitative Structure‐Property Relationships Modeling to Predict In Vitro and In Vivo Binding of Drugs to the Bile Sequestrant, Colesevelam (Welchol) , 2009, Journal of clinical pharmacology.

[103]  Johann Gasteiger,et al.  Ligand-Based Models for the Isoform Specificity of Cytochrome P450 3A4, 2D6, and 2C9 Substrates , 2007, J. Chem. Inf. Model..

[104]  P Veng-Pedersen,et al.  Application of neural networks to pharmacodynamics. , 1993, Journal of pharmaceutical sciences.

[105]  Sheila Annie Peters,et al.  Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Lineshape Analysis , 2008, Clinical pharmacokinetics.

[106]  M Paul Gleeson,et al.  Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis. , 2007, Journal of medicinal chemistry.

[107]  D. Mager,et al.  Quantitative structure–property relationships of camptothecins in humans , 2009, Cancer Chemotherapy and Pharmacology.

[108]  S. Curry,et al.  Structural basis of the drug-binding specificity of human serum albumin. , 2005, Journal of molecular biology.

[109]  Thierry Lavé,et al.  Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. , 2003, Journal of pharmaceutical sciences.

[110]  L. Hall,et al.  Molecular connectivity in chemistry and drug research , 1976 .

[111]  G. Grass,et al.  Effect of diverse datasets on the predictive capability of ADME models in drug discovery , 2001 .

[112]  Franco Lombardo,et al.  A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. , 2006, Journal of medicinal chemistry.

[113]  F. Theil,et al.  A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. , 2000, Journal of pharmaceutical sciences.

[114]  S. Ekins,et al.  Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.

[115]  Donald E Mager,et al.  Quantitative structure-pharmacokinetic/pharmacodynamic relationships. , 2006, Advanced drug delivery reviews.

[116]  G. Tucker,et al.  A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance , 2010, Clinical pharmacokinetics.

[117]  Walter Schmitt,et al.  A physiological model for the estimation of the fraction dose absorbed in humans. , 2004, Journal of medicinal chemistry.

[118]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[119]  P. Sinko,et al.  Estimating Human Drug Oral Absorption Kinetics from Caco-2 Permeability Using an Absorption-Disposition Model: Model Development and Evaluation and Derivation of Analytical Solutions for ka and Fa , 2005, Journal of Pharmacology and Experimental Therapeutics.

[120]  M. Bermejo,et al.  Validation of a biophysical drug absorption model by the PATQSAR system. , 1999, Journal of pharmaceutical sciences.

[121]  Anders Karlén,et al.  Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors. , 2004, Journal of medicinal chemistry.

[122]  S. Toon,et al.  Structure-pharmacokinetic relationships among the barbiturates in the rat. , 1983, The Journal of pharmacology and experimental therapeutics.